Indication Expansion and Drug Positioning - Opportunities for Translational Sciences

Lun Yang

Bayer, Germany

More than half drugs have multiple-indication potential. It is therefore reasonable to perform Indication expansion and choose the best indications for a drug molecule, which could be accomplished by using network pharmacology and big data technology. At Bayer, it has become standardized work stream in the pipeline. We believe that this procedure can be introduced to the entire pharmaceutical field. Large volume of the molecular data, real world evidence and commercial data could help indication prioritization, which could maximize the assets potential and deliver real value to the patients.